Test Price
2,800 AED✅ Home Collection Available
FGF12 Gene Early Infantile Epileptic Encephalopathy Type 47 (EIEE47) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity · ISO-Accredited Processing
Next-Generation Sequencing with proprietary bioinformatics pipeline achieves full-gene coverage and single-base resolution. Each run is validated against curated variant databases to eliminate false-positive and false-negative signals, ensuring diagnostic reliability for EIEE47.
VIP Mobile Phlebotomy & Cold-Chain Home Collection
Available daily from 8 AM to 11 PM. A licensed phlebotomist collects whole blood, extracted DNA, or a single drop on FTA card at your residence across all UAE emirates. Mandatory pre-collection genetic counselling and pedigree charting are completed prior to blood draw.
📋 Telephonic Post-Test Clinical Guidance: A board-certified genetic counsellor interprets results in the context of family history and EIEE47 phenotype. DHA-Recommended
📱 Instant Insurance Verification via WhatsApp: +971 54 548 8731 — coverage is confirmed before scheduling.
Test Overview & Methodology
This test sequences the entire coding region of the FGF12 gene to detect pathogenic variants causing Early Infantile Epileptic Encephalopathy Type 47 (EIEE47) – a severe neonatal-onset disorder characterised by refractory seizures, profound developmental delay, and movement abnormalities. Early molecular confirmation enables tailored anti-epileptic strategies, surveillance for comorbidities, and informed family planning. All clinically significant variants are confirmed by Sanger sequencing to eliminate false-positive errors.
| Feature | DNA Labs UAE Test | Alternative Syndrome Panel |
|---|---|---|
| Methodology | NGS with full FGF12 coverage, validated by Sanger confirmation of all variants | NGS panel of 30–100 genes; may miss deep intronic or regulatory mutations in FGF12 |
| Analytical Sensitivity | 99.9% for SNVs, indels, and copy-number changes | ~97% for SNVs or indels; CNV detection typically not included |
| Turnaround Time | 3–4 weeks with pre-report counsellor review | 4–8 weeks on average |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I emphasise that a confirmed FGF12 variant establishes the diagnosis of EIEE47, yet clinical management must always incorporate EEG findings, developmental assessments, and multidisciplinary input. Families should never modify anti-epileptic medications without direct medical supervision, as abrupt changes can provoke life-threatening seizure exacerbation. Genetic results are most informative when interpreted alongside comprehensive clinical evaluation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
Do not discontinue, adjust, or initiate any anti-epileptic drug therapy based solely on genetic findings without direct consultation with the prescribing physician. Abrupt medication changes may trigger status epilepticus or other life-threatening events. Always integrate molecular results with clinical and electroencephalographic data before modifying treatment.
Exclusion Criteria & Safety Red Flags
- Exclusion: Inability to provide a documented clinical history or pedigree chart; absence of legal guardian consent for minors as mandated by UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion: Active systemic infection or coagulopathy contraindicating venipuncture.
- Emergency Red Flag: If the proband develops status epilepticus, respiratory depression, or cardiopulmonary instability, redirect immediately to the nearest emergency department – genetic testing must not delay acute medical care.
- Data Red Flag: Variants of uncertain significance are clearly reported; do not base irreversible clinical decisions solely on a VUS result without further familial testing or functional studies.
Patient FAQ & Clinical Guidance
1. What sample is required for the FGF12 EIEE47 genetic test, and how is it collected at home?
Answer: A simple blood draw, buccal swab, or FTA card sample is collected by a licensed phlebotomist at your residence anywhere in Dubai, Abu Dhabi, or across the UAE. No special fasting, diet, or medication pause is required before collection. A mandatory pre-test genetic counselling session and pedigree charting are completed before the blood draw to ensure informed consent and accurate interpretation.
2. How accurate is the NGS test for FGF12-related encephalopathy, and are results confirmed?
Answer: Our next-generation sequencing achieves 99.9% analytical sensitivity and specificity for single-nucleotide variants, small insertions or deletions, and copy-number changes. Every clinically significant variant is independently confirmed by Sanger sequencing, eliminating false-positive errors and ensuring that the result is truly diagnostic for EIEE47.
3. Is this genetic test covered by insurance in the UAE, and how quickly can I receive the report?
Answer: Most UAE insurers cover medically indicated genetic testing upon pre-authorisation. We provide direct billing verification via WhatsApp at +971 54 548 8731. The final clinical report is delivered within 3–4 weeks from sample receipt, including pre-report counsellor review and interpretation.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All genetic data are processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimisation, and secure handling protocols are strictly enforced throughout the testing lifecycle. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE holds DHA Facility License Number 1143 and operates under the regulatory oversight of the Dubai Health Authority. Your genetic information is protected by industry-standard encryption and access controls, and is never shared with third parties without explicit written authorisation.
Clinical & Logistical Metadata
| Test Name | FGF12 Gene Early Infantile Epileptic Encephalopathy Type 47 (EIEE47) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G40.4 |
| LOINC Code | 82939-0 |
| DHA Facility License & Laboratory Address | License 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians